Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?

Blood Reviews

Volumn 27, Issue 1, 2013, Pages 55-62

  Chang, Ying Jun ^a   Huang, Xiao Jun ^a,b  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Tsinghua University   (China)

Author keywords

Donor lymphocyte infusion; Hematopoietic stem cell transplantation; Prophylaxis; Relapse; Treatment

Indexed keywords

CYCLOSPORIN A; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA ANTIGEN; METHOTREXATE; MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHIMERA; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; LEUKEMIA; LEUKEMIA RELAPSE; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; RISK ASSESSMENT;

CHIMERISM; ERYTHROID PRECURSOR CELLS; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNIZATION, PASSIVE; LYMPHOCYTE TRANSFUSION; PATIENT SELECTION; RECURRENCE; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84872160368     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.11.002     Document Type: Article

References (73)

1. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 2006, 354:1813-1826.
2. Passweg J.R., Baldomero H., Gratwohl A., et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012, 47:906-923.
3. Chang Y.J., Huang X.J. Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. Curr Opin Hematol 2012, 19:454-461.
4. Zhao X.S., Jin S., Zhu H.H., et al. Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant 2012, 47:499-507.
5. Wang Y., Liu D.H., Xu L.P., et al. Prevention of relapse using granulocyte CSF-primed PBPCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with advanced-stage acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant 2012, 47:1099-1104.
6. Huang X.J. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. Best Pract Res Clin Haematol 2011, 24:351-358.
7. Oran B., de Lima M. Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation. Curr Opin Hematol 2011, 18:388-394.
8. Deol A., Lum L.G. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010, 36:528-538.
9. Hasskarl J., Zerweck A., Wasch R., et al. Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft. Bone Marrow Transplant 2012, 47:277-282.
10. Huang X.J., Liu D.H., Liu K.Y., et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007, 92:414-417.
11. Huang X.J., Liu D.H., Liu K.Y., et al. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 2008, 28:276-283.
12. Huang X.J., Wang Y., Liu D.H., et al. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia-feasibility and safety study. J Clin Immunol 2008, 28:390-397.
13. Huang X.J., Wang Y., Liu D.H., et al. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect. Bone Marrow Transplant 2009, 44:309-316.
14. Maury S., Lemoine F.M., Hicheri Y., et al. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010, 2:41ra52.
15. Yan C.H., Liu D.H., Liu K.Y., et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012, 119:3256-3262.
16. Yan CH, Liu DH, Xu LP, et al. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant in press, [Electronic publication ahead of print]. doi:10.1111/j.1399-0012.2012.01618.x.
17. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
18. Choi S.J., Lee J.H., Kim S., et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant 2005, 36:163-169.
19. Guglielmi C., Arcese W., Dazzi F., et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002, 100:397-405.
20. Wang Y., Liu D.H., Fan Z.P., et al. Prevention of relapse using DLI can increase survival following HLA-identical transplantation in patients with advanced-stage acute leukemia: a multi-center study. Clin Transplant 2012, 26:635-643.
21. Campregher P.V., Gooley T., Scott B.L., et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2007, 40:965-971.
22. Levine J.E., Braun T., Penza S.L., et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002, 20:405-412.
23. Peggs K.S., Sureda A., Qian W., et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007, 139:70-80.
24. Hoevenaren I.A., van Vulpen L.F., Levenga H., et al. Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions. Bone Marrow Transplant 2011, 46:319-321.
25. Lokhorst H.M., Wu K., Verdonck L.F., et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004, 103:4362-4364.
26. Ritgen M., Stilgenbauer S., von Neuhoff N., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004, 104:2600-2602.
27. Ash S., Stein J., Askenasy N., et al. Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation. Br J Cancer 2010, 103:1597-1605.
28. Bethge W.A., Hegenbart U., Stuart M.J., et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004, 103:790-795.
29. Massenkeil G., Nagy M., Lawang M., et al. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003, 31:339-345.
30. Sohn S.K., Jung J.T., Kim D.H., et al. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002, 94:18-24.
31. Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5675-5687.
32. Lutz C., Massenkeil G., Nagy M., et al. A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:805-812.
33. Thomson K.J., Morris E.C., Milligan D., et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010, 28:3695-3700.
34. Peggs K.S., Kayani I., Edwards N., et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011, 29:971-978.
35. El-Cheikh J., Crocchiolo R., Furst S., et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp Hematol 2012, 40:521-527.
36. Kolb H.J., Mittermuller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990, 76:2462-2465.
37. Millot F., Guilhot J., Nelken B., et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006, 20:187-192.
38. Chen H., Liu K.Y., Xu L.P., et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol 2012, 5:29.
39. Klyuchnikov E., Sputtek A., Slesarchuk O., et al. Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:374-383.
40. Huang X., Guo N., Ren H., et al. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chin Med J (Engl) 2003, 116:736-741.
41. Choi S.J., Lee J.H., Kim S., et al. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia 2004, 18:1789-1797.
42. Dominietto A., Pozzi S., Miglino M., et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood 2007, 109:5063-5064.
43. Rettinger E., Willasch A.M., Kreyenberg H., et al. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood 2011, 118:5681-5688.
44. Warren E.H., Fujii N., Akatsuka Y., et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010, 115:3869-3878.
45. Roddie C., Peggs K.S. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther 2011, 11:473-487.
46. Peggs K.S., Thomson K., Hart D.P., et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004, 103:1548-1556.
47. Rutella S., Zavala F., Danese S., et al. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 2005, 175:7085-7091.
48. Anderlini P., Champlin R.E. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008, 111:1767-1772.
49. Abbi KK, Zhu J, Ehmann WC, et al. G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation. Bone Marrow Transplant in press, [Electronic publication ahead of print]. doi:10.1038/bmt.2012.144.
50. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25:4938-4945.
51. Zhang W., Choi J., Zeng W., et al. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res 2010, 16:2729-2739.
52. Zheng H., Matte-Martone C., Li H., et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 2008, 111:2476-2484.
53. Radojcic V., Pletneva M.A., Yen H.R., et al. STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol 2010, 184:764-774.
54. Young J.S., Wu T., Chen Y., et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol 2012, 189:222-233.
55. Wang X., Schmitt A., Chen B., et al. Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Exp Hematol 2010, 38:1066-1073.
56. Di Stasi A., Tey S.K., Dotti G., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011, 365:1673-1683.
57. Zhao X.S., Liu Y.R., Zhu H.H., et al. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2012, 91:183-192.
58. Hijiya N., Thomson B., Isakoff M.S., et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood 2011, 118:6043-6049.
59. Kang Y., Chao N.J., Aversa F. Unmanipulated or CD34 selected haplotype mismatched transplants. Curr Opin Hematol 2008, 15:561-567.
60. Bornhauser M., Thiede C., Platzbecker U., et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood 2011, 117:7174-7184.
61. Bader P., Kreyenberg H., Henze G.H., et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009, 27:377-384.
62. Waller E.K., Rosenthal H., Jones T.W., et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001, 97:2948-2956.
63. Huang X.J., Chang Y.J. Unmanipulated HLA-mismatched/haploidentical blood and marrow hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:197-204.
64. Dodero A., Carniti C., Raganato A., et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009, 113:4771-4779.
65. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
66. Stern M., Ruggeri L., Mancusi A., et al. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008, 112:2990-2995.
67. Ogawa H., Tamaki H., Ikegame K., et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003, 101:1698-1704.
68. Bruggemann M., Gokbuget N., Kneba M. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle. Semin Oncol 2012, 39:47-57.
69. Porter D.L., Collins R.H., Hardy C., et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000, 95:1214-1221.
70. Marcus A., Waks T., Eshhar Z. Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood 2011, 118:975-983.
71. Lu Y.F., Gavrilescu L.C., Betancur M., et al. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Blood 2012, 119:273-284.
72. Hill G.R. Vaccinating donors to improve GVL. Blood 2011, 118:5720-5721.
73. Li N., Matte-Martone C., Zheng H., et al. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood 2011, 118:5965-5976.